Health
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase 3 clinical studies of mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Dec. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase 3 clinical studies of mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1, DREAMS-2) have been published back-to-back in Nature as Accelerated Article Previews (AAP) [DREAMS-1i,DREAMS-2ii].","length":700,"tagName":"p"},{"type":"text","content":"The co-first authors of the DREAMS-1 article are Professor Dalong Zhu from Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School, and Professor Jiajun Zhao from Shandong Provincial Hospital affiliated with Shandong First Medical University. Dr. Lei Qian from Innovent Biologics serves as co-corresponding author alongside both co-first authors. For the DREAMS-2 article, the co-first authors are Professor Lixin Guo from Beijing Hospital and Professor Bo Zhang from China-Japan Friendship Hospital, with Professor Wenying Yang from China-Japan Friendship Hospital serving as the corresponding author.","length":624,"tagName":"p"},{"type":"text","content":"The Nature publication of mazdutide represents multiple historic breakthroughs. It marks the first time that Nature has published two Phase 3 clinical studies back-to-back in the field of metabolic and endocrine diseases, and mazdutide became the first China-developed drug to have two studies published simultaneously in Nature. Notably, mazdutide's first Phase 3 weight loss clinical study (GLORY-1) were published in The New England Journal of Medicine, making it the only GLP-1 therapy to reach the top journals of both Nature and NEJM. This achievement signifies the highest level of international academic recognition for China's drug development and biotech innovation. With its robust clinical data and groundbreaking mechanistic studies, mazdutide provides a "China Solution" in the global metabolic disease space. Together, Chinese clinicians and Innovent as a China-leading innovative pharmaceutical compa...